Papillary cystadenocarcinoma of the parotid gland: a rare sub-variant of salivary gland adenocarcinoma

Satya Dutta1, Biswajit Dey1, Jaya Mishra1, Vandana Raphael1, Jonali Das1, Donboklang Lynser2

How to cite: Dutta S, Dey B, Mishra J, Raphael V, Das J, Lynser D. Papillary cystadenocarcinoma of the parotid gland: a rare sub-variant of salivary gland adenocarcinoma. Autops Case Rep [Internet]. 2022;12:e2021357. https://doi.org/10.4322/acr.2021.357

Abstract

Papillary cystadenocarcinoma of the salivary gland is a very rare malignant neoplasm accounting for only 2% of all salivary gland lesions. In 1991 it was first included as a separate entity in the World Health Organization (WHO) classification of salivary gland tumors and in 2017 WHO Classification, the tumor was clubbed as a sub-variant of adenocarcinoma, not otherwise specified. It most commonly occurs in the major salivary glands. Herein we report a case of salivary papillary cystadenocarcinoma in a 54-year-old female, who presented with rapid enlargement of the right parotid swelling. Based on radiology and fine-needle aspiration cytology, a working diagnosis of the malignant tumor involving the superficial lobe of the right parotid gland was made. In view of the malignant nature of the swelling, superficial parotidectomy was done. The histopathology and immunohistochemistry of the mass confirmed the diagnosis of papillary cystadenocarcinoma of the right parotid. With the revised 2017 WHO classification of salivary gland tumors, it is important to report all rare subtypes in order to understand their biology and behavior.

Keywords:
Papillary cystadenocarcinoma; Salivary gland neoplasm; Parotid

INTRODUCTION

In 1991, the papillary cystadenocarcinoma was considered as a separate entity in the World Health Organization (WHO) classification of tumors of the salivary glands.1 Subsequently, the word ‘papillary’ was dropped in 2005 WHO classification since papillae were not always a prominent finding.2 In 2017 WHO classification, the tumor was clubbed as a sub-variant of adenocarcinoma-not otherwise specified (NOS).3 Papillary cystadenocarcinoma is one of the uncommon malignancies of the salivary glands accounting for only 2% of all salivary gland lesions.4 It is also known as malignant papillary cystadenoma, mucin-producing adenopapillary carcinoma, and low-grade papillary adenocarcinoma.2 It most commonly occurs in the parotid gland, followed by the sublingual gland and minor salivary glands.2 Papillary
Papillary cystadenocarcinoma of the parotid gland: A rare sub-variant of salivary gland adenocarcinoma

Cystadenocarcinoma is characterized by cysts and papillary endocystic projections but lacks the features of cystic variants of several common salivary gland carcinomas like polymorphous low-grade adenocarcinoma (PLGA), salivary duct carcinoma, mucoepidermoid carcinoma, and the papillary cystic variant of acinic cell carcinoma. Herein, we describe a case of papillary cystadenocarcinoma of the parotid gland.

CASE REPORT

A 54-year-old female presented with the chief complaint of rapid enlargement of the right parotid swelling for eight months. It was associated with pain; however, she did not have any history of fever, cough, or chest pain. General and systemic examinations were normal. On local examination, the swelling was present over the right parotid region measuring 7x5.5 cm. It was firm in consistency and had restricted mobility. The overlying skin was unremarkable, with no color change, ulceration, or puckering. No cervical lymph node was palpable.

Magnetic resonance imaging (MRI) revealed a lobulated mass in the superficial lobe of the right parotid, which was T1 hypointense and T2 hyperintense suggestive of a malignant lesion (Figure 1A and 1B).

Fine-needle aspiration cytology (FNAC) performed from the right parotid swelling was reported as malignant (category VI) as per the “Milan System for Reporting Salivary Gland Cytopathology” (MSRSGC).

In view of the malignant nature of the swelling, superficial parotidectomy was done. Grossly, the specimen was circumscribed and globular measuring 8x6x4 cm. At the cut surface, it was mostly solid with a cystic area. The cystic areas were filled with mucoid-like material (Figure 2A). The histopathological examination showed many complex papillary fronds with fibrovascular cores, and lined by tall columnar epithelium. The cells exhibited round vesicular eccentric nuclei and slightly granular cytoplasm. Few cells showed cytoplasmic vacuolation. Intracellular mucin was also noted (Figure 2B and 2C). The tumor cells were positive for CK 7 and CK AE1/AE3 (Figure 2D).

Other markers like CK 20, CK 19, Vimentin, DOG-1, androgen receptor, Her2neu, Gross Cystic Disease Fluid Protein-15 (GCDFP-15), CDX2, and TTF1 were negative. Myoepithelial markers like p63, S-100, Calponin, and Smooth muscle actin (SMA) were negative. The Ki67 index was 8%. In view of these findings, the diagnosis of papillary cystadenocarcinoma of the right parotid was made. The patient was discharged on the 7th post-operative day. There was no locoregional recurrence after 6 months of follow-up.

DISCUSSION

Salivary gland cystadenocarcinoma is a rare group of epithelial malignancy with indolent biological behavior. Most salivary gland cystadenocarcinomas occur in the major salivary glands (65%) followed by minor salivary glands (35%). Among the major salivary glands, the most common site is the parotid glands.
followed by the sublingual glands. A search using the keywords ‘papillary cystadenocarcinoma’ and ‘parotid’ in PubMed revealed 36 results. After excluding articles in languages other than English, articles describing papillary cystadenocarcinomas in sites other than parotid glands, and descriptive articles without full or specific information regarding the histologic type or site, 12 articles were included for a review. A similar search in Google Scholar yielded four additional articles, which were included in this review. A total of 16 articles were reviewed comprising 79 cases of papillary cystadenocarcinoma of the parotid gland. (Table 1) 

Papillary cystadenocarcinoma is usually a slow-growing, compressible asymptomatic mass. Around 71% of the patients are over 50 years of age. Although no sex predilection has been documented by Foss et al. for salivary gland PCAC, an analysis of the parotid papillary cystadenocarcinoma shows most cases are documented in males with almost all cases presenting over 50 years of age. (Table 1) The present case was a female patient and was over 50 years of age at the time of presentation.

MRI is critical in determining the nature of the lesion, whether solid, cystic, or necrotic, as well as its relationship to the salivary gland, adjacent structures, and the extent of infiltration due to its excellent spatial resolution and superior soft-tissue contrast. The present case had both solid and cystic areas and infiltrated the adjacent structures.

The diagnostic accuracy of pre-operative FNAC of salivary gland tumors ranges from 80-95%. However,
Papillary cystadenocarcinoma of the parotid gland: A rare sub-variant of salivary gland adenocarcinoma

The exact typing of salivary gland tumors on FNAC often poses a problem due to cytological overlap. The present case was typed as malignant (category VI) as per the MSRSGC. Microscopically papillary cystadenocarcinoma of the salivary gland is characterized by cystic and solid areas with multiple luminal papillary projections having a fibrovascular core and lined by cuboidal, columnar, or mucus-secreting epithelial cells. The tumor cells show mild to moderate nuclear atypia with one or two small distinct hyperchromatic nucleoli and eosinophilic to vacuolated cytoplasm. Papillary cystadenocarcinoma must be distinguished from its benign counterpart cystadenoma based on the former’s infiltrative growth pattern into adjacent surrounding tissues and atypical nuclear features.

Table 1. Cases of papillary cystadenocarcinoma of parotid gland reported in the English literature

| Ref | # cases | Age (Y) | Sex | Size (cm) | Duration | Side | Grade | IHC |
|-----|---------|---------|-----|-----------|----------|------|-------|-----|
| 5   | 9       | a.m 45.7 | F   | 62        | M 10.8 y | NA   | NM    | Positive CK (KL1 & K8.12), Vimentin & MAM-6; varying intensity for S-100 & NSE |
| 6   | 35      | a.m 58.8 | M=F | 62        | 0.4 to 0.6 | 1 m - 5 y | 19 right, 13 left, 3 cases | NM |
| 7   | 2       | 60      | M   | 4x 2      | 6 m - 14 y | NA   | LG    | NM |
| 8   | 1       | 33      | F   | 4x 3      | 5 m      | Left  | LG    | Positive CK AE1/AE3 & CEA |
| 9   | 1       | 62      | M   | 1.5 X 1.5 | NM       | NM    | LG    | Weak positivity for S-100, Negative Vimentin & SMA |
| 10  | 1       | 34      | M   | 6x 6      | 10 y     | Right | LG    | NM |
| 11  | 1       | 55      | M   | 3         | 3 m      | Right | LG    | Positive CK & EMA, Negative TTF-1 |
| 12  | 1       | 57      | M   | 6x 5      | 2 y      | Right | LG    | Positive CK7, EMA & S-100, Negative CEA, SMA, GFAP, ER, PR & Her2neu |
| 13  | 1       | 40      | F   | 1.5X0.5   | 10 y     | Right | LG    | NM |
| 14  | 1       | 33      | F   | 4x 3      | 5 m      | Left  | LG    | NM |
| 15  | 1       | 58      | M   | 5x4x2     | 4 m      | Right | NM    | NM |
| 16  | 1       | 55      | M   | 6 x 5     | 3 y      | Right | NM    | Positive CK7, Negative CK20, p63 & Cerb2 |
| 17  | 1       | 47      | M   | 9x6.5x3   | 4 y      | Right | IG    | NM |
| 18  | 1       | 51      | M   | 3.3 x 3.2 x 2.8 | 4 y | Right | HG    | NM |
| 19  | 19      | a.m 49.55 | M=66.7% | <3-29.6% | ≤ 12 m-59.3% | 13-36 m-25.9% | Right-55.6% | NM |
| 20  | 1       | 67      | F   | 6x 5 cm   | 6 months | Right | LG    | NM |

a.m= arithmetic mean; F= female; HG= high grade; IG= intermediate grade; LG= low grade; m= month; M= male; NM= not mentioned; y= year.
The closest differential diagnoses include PLGA, papillary cystic variant of acinic cell carcinoma, salivary duct carcinoma, and mucoepidermoid carcinoma. The various morphologic and immunohistochemical characteristics of these entities are summarized in Table 2.

The other uncommon differential diagnoses are mucinous adenocarcinoma and intestinal-type adenocarcinoma, and metastatic papillary carcinoma of the thyroid. Papillary carcinoma of the thyroid shows characteristic nuclear features and expresses nuclear positivity for thyroid transcription factor 1 (TTF-1). Mucinous adenocarcinoma and intestinal-type adenocarcinoma are two other uncommon subtypes of adenocarcinoma-NOS, which need to be differentiated from papillary cystadenocarcinoma as these tumors have an aggressive clinical course. Histopathologically, mucinous adenocarcinoma is characterized by large pools of extracellular mucin and immunopositive for CK 7. Intestinal-type adenocarcinoma is positive for CK 20 and CDX2.

In the present case, characteristic morphology showing multiple luminal papillary projections having fibrovascular cores, which were lined by tall columnar and mucinous cells, pointed to a diagnosis of papillary cystadenocarcinoma. Immunopositivity for CK 7 and CK AE1/AE3, and negativity for other epithelial, myoepithelial, and specific markers for other salivary tumors were consistent with papillary cystadenocarcinoma.

Salivary gland papillary cystadenocarcinoma is a low-grade tumor with an indolent clinical course. However, there are isolated cases of salivary papillary cystadenocarcinoma with aggressive behavior in the form of high mitotic activity and cervical nodal

Table 2. Differentiating features (histomorphology and immunohistochemistry) of the differential diagnoses of papillary cystadenocarcinoma

| Entity                      | Most common site | Tumor architecture                                                                 | Tumor cells                                                                 | Cytokeratin | Calponin/ SMA | Other IHC markers                  |
|-----------------------------|------------------|------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|-------------|---------------|------------------------------------|
| PLGA                        | Minor salivary glands | Variable patterns of different proportions including trabecular, tubular, papillary, solid and cribriform patterns | tumor cells having pale nuclei with marked chromatin clearing               | Positive for CK7, CK AE1/AE3 | Variable | Positive for Vimentin and S-100 |
| Papillary cystic variant of acinic cell carcinoma | Parotid glands | Transition of usual dense cellularity into papillary folds interspersed with cystic spaces. | Diverse tumor cell types including acinic cells, vacuolated cells, intercalated cells, non-specific glandular cells forming 'hobnail cells' and clear cells | Positive for CK7 | Negative | Positive for DOG-1 |
| Salivary duct carcinoma     | Parotid glands   | Invasive tumor forming cords, nests and cribriform glands in a desmoplastic stroma | Tumor cells have ample eosinophilic cytoplasm showing marked nuclear pleomorphism | Positive for CK7, CK AE1/AE3 | Negative | Positive for Androgen receptor, Her2neu, and GCDFP-15 |
| Mucoepidermoid carcinoma    | Parotid glands   | Incompletely encapsulated or unencapsulated tumor showing papillary or glandular growth pattern | Varying proportions of Squamoid, intermediate cells, and mucophages | Positive for CK7, CK19 | Negative | Positive for p63 |
| Papillary cystadenocarcinoma | Parotid glands   | Cysts with papillary endocystic projections | Cuboidal to tall columnar cells with vesicular nuclei and slightly granular cytoplasm | Positive for CK7, CK AE1/AE3 | Negative | Negative for S-100, DOG-1, AR, Her2neu, GCDFP-15, p63 |
metastasis. The treatment of choice is complete surgical excision (superficial parotidectomy). High-grade tumors require neck dissection.

The present case describes a rare sub-variant of adenocarcinoma-NOS of the salivary gland, which is no more included in the newer WHO classification. However, it is important to report all rare sub-variants in order to understand their biology and behavior.

REFERENCES

1. Seifert G, Sobin LH. Histological classification of salivary gland tumours. 2nd ed. Berlin: Springer-Verlag; 1991.
2. Auclair PL. Cystadenocarcinoma. In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. Pathology and genetics of head and neck tumours. Lyon: IARC; 2005. (World Health Organization Classification of Tumours; pp. 232-33).
3. El-Naggar AK, Chan JKC, Grandis JR, Takata T, Grandis J, Slootweg P. WHO classification of head and neck tumours. 4th ed. Lyon: IARC; 2017.
4. Ellis GL, Auclair PL. Tumour of the salivary glands. Washington, DC: Armed Forces Institute of Pathology; 2008. (Atlas of tumour pathology series; 4. pp. 281-9).
5. Shrestha P, Namba M, Yang L, Liu B, Oosumi H, Mori M. Papillary cystadenocarcinoma of salivary-glands - an immunohistochemical study. Int J Oncol. 1994;4(3):587-97. http://dx.doi.org/10.3892/ijo.4.3.587. PMid:21566964.
6. Foss RD, Ellis GL, Auclair PL. Salivary gland cystadenocarcinomas. A clinicopathologic study of 57 cases. Am J Surg Pathol. 1996;20(12):1440-7. http://dx.doi.org/10.1097/00000478-199612000-00002. PMid:8940436.
7. Klijianenko J, Vielh P. Salivary carcinomas with papillae: cytology and histology analysis of polymorphous low grade adenocarcinoma and papillary cystadenocarcinoma. Diagn Cytopathol. 1998;19(4):244-9. http://dx.doi.org/10.1002/(SICI)1097-0339(199810)19:4<244::AID-DC3>3.0.CO;2-A. PMid:9784985.
8. Kapila K, Verma K. Cytomorphologic features of papillary cystadenocarcinoma of the parotid. Diagn Cytopathol. 2002;26(6):392-7. http://dx.doi.org/10.1002/dc.10110. PMid:12112832.
9. Simionescu C, Florescu M, Margaritescu C, Marinescu M. Histopathological and immunohistochemical study in one case of cystadenoma of parotid gland becoming malignant. Rom J Morphol Embryol. 1999;45:159-164.
10. Gallego L, Junquera L, Fresno MF, Vicente JC. Papillary cystadenoma and cystadenocarcinoma of salivary glands: two unusual entities. Med Oral Patol Oral Cir Buccal. 2008;13(7):E460-3. PMid:18587312.
11. Agarwal S, Das P, Singh MK, Sharma A, Karak AK. Papillary cystadenocarcinomas of salivary glands with oncocytic epithelial lining: report of 2 cases. Int J Surg Pathol. 2008;16(3):341-4. http://dx.doi.org/10.1177/1066896907309580. PMid:18573791.
12. Aloudah NM, Raddaoui E, Aldhahri S, Al-Abbadi MA. Low-grade papillary cystadenocarcinoma of the parotid gland: presentation of a case with cytological, histopathological, and immunohistochemical features and pertinent literature review. Diagn Cytopathol. 2009;37(2):128-31. http://dx.doi.org/10.1002/dc.20971. PMid:19021236.
13. Telugu RB, Job AJ, Manepadam MT. Papillary cystadenocarcinoma of the parotid gland: a rare case report. J Clin Diagn Res. 2016;10(6):ED01-3. http://dx.doi.org/10.7860/JCDR/2016/17750.7907. PMid:27504297.
14. Joshi U, Chufal SS, Thapliyal N, Khetan H. Cytomorphological features of papillary cystadenocarcinoma of parotid gland: a case report with review of literature. Cytojournal. 2016;13:12. http://dx.doi.org/10.4103/1742-6413.182955. PMid:27298629.
15. Jindal S, Handa U. Cytological diagnosis of papillary cystadenocarcinoma of the parotid gland. Ann Clin Cytol Pathol. 2015;1(2):1009.
16. Khatib Y, Dande M, Patel RD, Kane SV. Cytomorphological findings and histological correlation of papillary cystadenocarcinoma of the parotid: not always a low-grade tumor. Indian J Pathol Microbiol. 2016;59(3):368-71. http://dx.doi.org/10.4103/0377-4929.188114. PMid:27510680.
17. Saraihe OA, Eid S. Parotid duct bleeding, presentation of malignant parotid gland papillary cystadenocarcinoma: rare case report. J Otolaryngol ENT Res. 2018;10(4):233-5. http://dx.doi.org/10.15406/joentr.2018.10.00352.
18. Wang KY, Kim DH, Xu Y, Rad MG, Lincoln CM. High-grade Features of papillary cystadenocarcinoma of the parotid gland. Oman Med J. 2019;34(2):164-8. http://dx.doi.org/10.5001/omj.2019.30. PMid:30918612.
19. Guo B, Cao YA, Qin X, Ma C. The rare entity of cystadenocarcinoma (CAC) in parotid gland: a single-center experience. J Cranio-maxillofac Surg. 2019;47(5):826-31. http://dx.doi.org/10.1016/j.jcms.2019.02.005. PMid:30857928.
20. Chowdhury Z, Mishra J, Shunyu NB. Papillary cystadenocarcinoma of salivary gland: report of a diagnostic pitfall and literature review. Ann Int Med Den Res. 2020;6(4):PT12-5.
21. Koç M, Yanilmaz M, Yıldırım H, Gök U, Cobanoğlu B. MRI findings of papillary cystadenocarcinoma of the
submandibular gland. Diagn Interv Radiol. 2010;16(1):20-3. PMid:20039236.

22. Zhu S, Schuerch C, Hunt J. Review and updates of immunohistochemistry in selected salivary gland and head and neck tumors. Arch Pathol Lab Med. 2015;139(1):55-66. http://dx.doi.org/10.5858/arpa.2014-0167-RA. PMid:25549144.

23. Kobayashi I, Kiyoshima T, Ozeki S, et al. Immunohistochemical and ultrastructural study of a papillary cystadenocarcinoma arising from the sublingual gland. J Oral Pathol Med. 1999;28(6):282-6. http://dx.doi.org/10.1111/j.1600-0714.1999.tb02040.x. PMid:10426203.

24. Pollett A, Perez-Ordonez B, Jordan RC, Davidson MJ. High-grade papillary cystadenocarcinoma of the tongue. Histopathology. 1997;31(2):185-8. http://dx.doi.org/10.1046/j.1365-2559.1997.2270840.x. PMid:9279572.

This study was carried out at the North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Mawdiangdiang, Shillong, India

**Authors’ contributions:** Satya Dutta, Biswajit Dey, and Jonali Das wrote the manuscript. Jaya Mishra and Vandana Raphael diagnosed the histopathology of the case. Donboklang Lynser reported the radiology. All authors collectively proof read the manuscript and approved the final version for publication.

**Ethics statement:** The informed consent signed by the patient authorizing publication is retained by the authors. The manuscript is by the Institutional Ethics rules.

**Conflict of interest:** The authors have no conflict of interest to declare.

**Financial support:** The authors declare that no financial support was received.

**Submitted on:** July 23rd, 2021

**Accepted on:** January 23rd, 2022

**Correspondence**

Jaya Mishra
North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS), Department of Pathology
Meghalaya, 793018, Mawdiangdiang, Shillong, India
Phone: +91 (94) 3633-4487
publicationmail@rediffmail.com